D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia

Schizophrenia Research

Volumn 131, Issue 1-3, 2011, Pages 69-74

  Gottlieb, Jennifer D ^a,b   Cather, Corinne ^b,c   Shanahan, Meghan ^b   Creedon, Timothy ^b   Macklin, Eric A ^b,c   Goff, Donald C ^b,c  

^a DARTMOUTH PSYCHIATRIC RESEARCH CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cognitive behavioral therapy; D cycloserine; Delusions; NMDA receptor hypofunction; Psychosis; Schizophrenia

Indexed keywords

CYCLOSERINE; NEUROLEPTIC AGENT; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITION; COGNITIVE THERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELUSION; DISEASE DURATION; DISEASE SEVERITY; DISTRESS SYNDROME; DOUBLE BLIND PROCEDURE; ETHNICITY; FEMALE; HUMAN; LEARNING; MALE; OUTPATIENT; PRIORITY JOURNAL; PSYCHOTIC SYMPTOM RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCALE FOR THE ASSESSMENT OF POSITIVE SYMPTOMS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE DRUG DOSE; UNEMPLOYMENT;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES; COGNITIVE THERAPY; CULTURE; CYCLOSERINE; DELUSIONS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 80051781845     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.05.029     Document Type: Article

References (26)

1. Andreasen N.C. The scale for the assessment of positive symptoms (SAPS) 1984, Iowa City: Iowa, The University of Iowa.
2. Beneyto M., Meador-Woodruff J.H. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008, 33(9):2175-2186. Aug.
3. Bentall R.P., Corcoran R., Howard R., Blackwood N., Kinderman P. Persecutory delusions: a review and theoretical integration. Clin. Psychol. Rev. (Special Issue: Psychosis) 2001, 21(8):1143-1192. Nov.
4. Davis M., Ressler K., Rothbaum B.O., Richardson R. Effects of d-cycloserine on extinction: translation from preclinical to clinical work. Biol. Psychiatry 2006, 60(4):369-375.
5. Dravid S.M., Burger P.B., Prakash A., et al. Structural determinants of d-cycloserine efficacy at the NR1/NR2C NMDA receptors. J. Neurosci. 2010, 30(7):2741-2754.
6. Dudley R.E., John C.H., Young A.W., Over D.E. Normal and abnormal reasoning in people with delusions. Brit. J. Clin. Psychol. 1997, 36:243-258.
7. Duffy S., Labrie V., Roder J.C. D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning. Neuropsychopharmacology 2008, 33(5):1004-1018. Apr.
8. Garety P.A., Hemsely D.R., Wessely S. Reasoning in deluded schizophrenic and paranoid patients: biases in performance on a probabilstic inference task. J. Nerv Ment. Dis. 1991, 179:194-201.
9. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 2001, 158:1367-1377.
10. Goff D., Tsai G., Levitt J., et al. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psych. 1999, 56:21-27.
11. Goff D.C., Cather C., Gottlieb J.D., et al. Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr. Res. 2008, 106(2-3):320-327. Dec.
12. Haddock G., McCarron J., Tarrier N., Faragher E.B. Scales to measure dimensions of hallucinations and delusions: the Psychotic Symptom Rating Scales (PSYRATS). Psychol. Med. 1999, 29(4):879-889.
13. Hillman B.G., Gupta S.C., Stairs D.J., Buonanno A., Dravid S.M. Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory. Neurobiol. Learn. Mem. 2011, 95(4):404-414. Feb.
14. Holt D.J., Lebron-Milad K., Milad M.R., et al. Extinction memory is impaired in schizophrenia. Biol. Psychiatry 2009, 65(6):455-463.
15. Kandel E.R. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001, 294(5544):1030-1038.
16. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160(1):13-23. Jan.
17. Langton J.M., Richardson R. d-cycloserine facilitates extinction the first time but not the second time: an examination of the role of NMDA across the course of repeated extinction sessions. Neuropsychopharmacology 2008, 33(13):3096-3102. Dec.
18. Manoach D.S., Cain M.S., Vangel M.G., Khurana A., Goff D.C., Stickgold R. A failure of sleep-dependent procedural learning in chronic, medicated schizophrenia. Biol. Psychiatry 2004, 56(12):951-956.
19. Norberg M.M., Krystal J.H., Tolin D.F. A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biol. Psychiatry 2008, 63(12):1118-1126.
20. Parnas A.S., Weber M., Richardson R. Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats. Neurobiol. Learn. Mem. 2005, 83(3):224-231. May.
21. Quartermain D., Mower J., Rafferty M.F., Herting R.L., Lanthorn T.H. Acute but not chronic activation of the NMDA-coupled glycine receptor with d-cycloserine facilitates learning and retention. Eur. J. Pharm. 1994, 257:7-12.
22. Roesler R., Vianna M., Sant'Anna M.K., Kuyven C.R., Kruel A.V., Quevedo J., Ferreira M.B. Intrahippocampal infusion of the NMDA receptor antagonist AP5 impairs retention of an inhibitory avoidance task: protection from impairment by pretraining or preexposure to the task apparatus. Neurobiol. Learn. Mem. 1998, 69(2):87-91. Mar.
23. Sanders M.J., Fanselow M.S. Pre-training prevents context fear conditioning deficits produced by hippocampal NMDA receptor blockade. Neurobiol. Learn. Mem. 2003, 80(2):123-129. Sep.
24. Wittenberg G.M., Tsien J.Z. An emerging molecular and cellular framework for memory processing by the hippocampus. Trends Neurosci. 2002, 25(10):501-505. Oct.
25. Wykes T., Steel C., Everitt B., Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr. Bull. 2008, 34(3):523-537.
26. Yaka R., Biegon A., Grigoriadis N., et al. d-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J. 2007, 21(9):2033-2041. Jul.